﻿Future directions in cancer immunotherapy with monoclonal antibodies

Introduction: Cancer immunotherapy with monoclonal antibodies (mAbs) has become a therapy with great potential nowadays. It is based on the affinity of antibodies to bind to specific molecules, thus inhibiting the growth and spread of cancer. There is a wide variety of mAbs with differentiated mechanisms and enormous clinical benefits. However, different immunotherapeutic alternatives have emerged due to their limitations, such as the long duration of organ toxicity and the inability to penetrate intracellularly. This mini-review will discuss the emerging alternatives of cancer immunotherapies based on mAbs.
 Bispecific antibodies (BsAbs): Antibodies designed to bind to two epitopes of an antigen.
 Antibody fragments: Fragments of the Fab region generated from the variable region of IgG and IgM and a scFv.
 Antibody-drug conjugates (ADCs): Administration of mAbs and a toxin of high specificity for a tumour target.
 Nanobodies (or nanocomponents): Small fragments of antibody heavy chain.
 Intrabodies (or intracellular antibodies): Antibodies that are expressed intracellularly and synthesised inside cells by retroviral delivery systems.
 Stereospecific and catalytic mAbs: Antibodies that recognise the 3D configurations of target molecules.
 Combination immunotherapies: Therapies that combine cytokines with tumour-targeted mAbs.
 Small molecule immunotherapeutics: Small molecule drugs that can stimulate intracellular pathways primarily involved in immune cell checkpoints and bind to mAb-like targets.
 Conclusion: These new varieties of immunotherapy present significant advantages, but future research should continue to improve their efficacy and safety and identify new biomarkers.
 Graphical abstract:
 
 
